US pharma major Eli Lilly will invest over $1 billion in India over the next few years, the company announced. Lilly, which manufactures weight-loss and diabetes drug Mounjaro, will upgrade the capacity of its existing facilities and establish a new manufacturing and quality hub in Hyderabad. The company has a commercial site in Gurugram and a specialised site in Bengaluru.